用口服abrocitinib成功治疗SAPHO综合征:一个病例报告
Zhipeng Lin1, Songyi Piao1, Rongxin Zhang1
1Department of Dermatology, The Second Hospital of Dalian Medical University, Dalian, China.
The Journal of dermatological treatment
|December 9, 2024
概括
阿布罗西提尼布是一种JAK1抑制剂,显示出对治疗Synovitis,,Pustulosis,Hyperostosis和骨质炎 (SAPHO) 综合征的希望. 这种治疗导致了显著的症状改善,并且在患有晚期疾病的患者中耐受良好.
科学领域:
- 类风湿病学 类风湿病学
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
背景情况:
- 萨福综合征是一种罕见的自身免疫性疾病,具有明显的皮肤和骨表现.
- 对于快速进展的SAPHO综合征病例,传统疗法可能不足.
研究的目的:
- 评估JAK1抑制剂abrocitinib在SAPHO综合征治疗中的有效性和安全性.
- 评估abrocitinib作为耐火性SAPHO综合征的潜在治疗方法.
主要方法:
- 一个病例研究,一个患有加速SAPHO综合征进展的患者对传统治疗没有反应.
- 治疗包括每天口服100毫克abrocitinib.
主要成果:
- 在3个月内,SAPHO综合征症状显著改善,包括皮肤病变的消失.
- 在15个月的abrocitinib治疗后,关节疼痛完全缓解.
- 在18个月的随访期间,没有观察到任何不良事件或疾病复发.
结论:
- 阿布罗西替尼单一治疗显示出作为SAPHO综合征有效治疗的潜力.
- 这种JAK1抑制剂为患有SAPHO综合征的患者提供了有前途的治疗途径,包括那些患有严重或耐火性疾病的患者.
相关概念视频
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:21Inflammatory Bowel Disease V: Surgical Management
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD: